Navigation Links
Adventrx Announces Positive Data From Multidrug Therapy With,CoFactor

Data Presented at American Association for Cancer Research Annual Meeting

SAN DIEGO, April 18, 2007 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. , a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, today announced positive results from preclinical studies using a multidrug treatment regimen including ANX-510 (CoFactor(R)) at the American Association for Cancer Research (AACR) Annual Meeting. Treatment with a regimen including CoFactor with 5-fluorouracil (5-FU) and capecitabine (Xeloda(R)), an oral prodrug of 5-FU, demonstrated superior inhibition of tumor growth and longer survival, with lower systemic toxicity compared with treatment groups containing leucovorin or capecitabine alone in a colorectal tumor model. An abstract entitled "Antitumor activity and safety of a hybrid treatment regimen of 5,10-methylenetetrahydrofolate, 5-fluorouracil, and capecitabine in a colorectal tumor xenograft model" was presented yesterday by the study's lead author Mark Cantwell, Ph.D., the Company's vice president of research and development.

"We believe CoFactor has the potential to improve fluoropyrimidine chemotherapies and reduce toxicity in multiple treatment regimens," said Evan M. Levine, ADVENTRX chief executive officer. "Based on these and other data, we are continuing to evaluate various treatment combinations to identify additional commercial opportunities and expand the value of CoFactor."

Tumor-bearing mice treated with CoFactor, 5-FU and capecitabine had the greatest inhibition of tumor growth compared to the other drug regimens tested in this study, including capecitabine alone and a matched treatment regimen of leucovorin (LV), 5-FU, and capecitabine. The mean tumor volume of the CoFactor, 5-FU and capecitabine-treated mice (288.5 mm3 +/- 32.6, mean +/- SEM) was statistical
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:12/19/2014)... Ill. , Dec. 19, 2014   Hospira, ... leading provider of injectable drugs and infusion technologies, today ... Morgan 33rd Annual Healthcare Conference on Wednesday, Jan. 14, ... presentation is scheduled to begin at 10:30 a.m. Pacific ... available to all interested parties through a live audiocast ...
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, ... SRNE ;  Sorrento), an oncology company developing new ... Inc., a privately-held immuno-oncology company developing proprietary Neukoplast ... based therapy, announced today that the companies have ... next generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for ...
(Date:12/19/2014)... LOS ALTOS, Calif. , Dec. 18, 2014 ... of a new generation of equipment for the ... today the release of the new Luminary™ Profiler, ... highly accurate light-based measurement in a cost-effective, portable ... to meet the specific needs of the cannabis ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2
... October 12, 2011 Leading health ... titles freely available through UN developing world research access ... scientific, technical and medical information products and services, today ... books to Research4Life , a public-private partnership working ...
... Mass., Oct. 11, 2011 Boston Scientific Corporation (NYSE: ... results for the third quarter ended September 30, 2011 on ... call will be hosted by Hank Kucheman, who becomes Boston ... Executive Vice President and Chief Financial Officer. A ...
Cached Medicine Technology:Elsevier Offers 950 New Health Titles to Research4Life 2Elsevier Offers 950 New Health Titles to Research4Life 3Boston Scientific To Webcast Conference Call Discussing Third Quarter 2011 Financial Results 2
(Date:12/21/2014)... As testosterone therapy lawsuit filings ... blood clots from using testosterone products such as AndroGel ... that the male hormone testosterone may increase the risk ... in the Proceedings of the National Academy of Sciences ... of male rats with naturally occurring colon cancer. Dr. ...
(Date:12/21/2014)... December 21, 2014 Concept Plus, LLC. ... firm headquartered in Fairfax, VA., today announced it has ... Fast 50 list, which ranks the fastest growing government contracting ... 2009 to 2013. , This is the first year that ... ranked # 20 with a 95.92% compound annual growth rate. ...
(Date:12/20/2014)... 2014 MissyDress, a distinguished special dress ... lovers. The business has drastically cut prices to all ... everyone until Jan. 30, 2015. Many of the hottest ... V-neck dresses, lace dresses, and more. , A spokesman ... every day. Whether A-line princess prom dresses or sweetheart ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 Dress company LunaDress ... dresses, and announced its Christmas Sale, offering big discounts on ... “Every girl has an idea to own a perfect wedding ... for your wedding dress, then come to LunaDress. Many different ... for you. Visit our website now and enjoy the current ...
(Date:12/20/2014)... News) -- The holidays can be anything but joyous ... trees, scented candles and other allergy triggers. "The ... have been packed away in dank basements or dusty ... patients," Dr. Rachna Shah, an affiliate faculty member at ... Loyola news release. Shah, who is also an ...
Breaking Medicine News(10 mins):Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:Concept Plus, LLC. Named One of Washington Technology’s Fast 50 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2Health News:Holiday Trimmings Can Trigger Allergies 2
... AUSTIN, Texas, May 21 From June 9-11 in ... lead a "DRTV Management Boot,Camp" tailor-made for nutraceutical and ... can do very well in an,informercial or short form ... from Iceland Health, for example," says Sarnow. "But there ...
... Georgacas and Mark ... Mishek as its newest members, ... Board of Directors of ClearWay Minnesota(SM) approved $1.4 million in,new ... to reduce exposure to secondhand smoke by advancing smoke-free,policy efforts ...
... research into the causes of cervical cancer appears to lend ... that could help prevent the disease. , According to a ... Chapel Hill, persistent infection with human papillomavirus (HPV) could be ... the second most common cancer in women worldwide. , ...
... QVC,s Pink Ribbon Beauty Broadcast Benefits the Breast Cancer ... Shoppers are sure to be,tickled pink this May when ... on Tuesday, May 27 at 1 AM (ET) and ... from top beauty,brands, with a portion of the proceeds ...
... to give keynote speech June 9 in Atlanta, ... U.S. Centers for Disease Control and Prevention (CDC), will,discuss ... address at the American Water Works Association,s Annual Conference,& ... Georgia., As one of the leading public health ...
... In this challenging,marketplace, pharmaceutical sales people have ... to effectively,represent their brands and ensure that ... Practices, LLC,s white paper "Best Practices in ... ) addresses how the Sales force,effectiveness and ...
Cached Medicine News:Health News:Direct Response TV Course on Nutraceutical/Cosmeceutical Products to Premiere in New York City 2Health News:ClearWay Minnesota(SM) Board Approves $1.4 Million in New Grants to Reduce Tobacco's Harm 2Health News:ClearWay Minnesota(SM) Board Approves $1.4 Million in New Grants to Reduce Tobacco's Harm 3Health News:UNC study firms up promise of potential new cervical cancer screening tool 2Health News:A Touch of Pink Never Looked So Good 2Health News:CDC Director to Address Public Health and Drinking Water at ACE08 2
... CMGS-1 Color Mini-Ganzfeld Stimulator is an advanced, ... integrated with your existing LKC system or ... visual electrodiagnostic test systems. Using LKCs ... smallest commercial Ganzfeld to meet ISCEV (International ...
... UTAS-E 3000 is the most advanced ... and accurate measurements of retinal and ... easy-to-use software available drives this powerful ... as adjustable contrast pattern stimulation, rapid ...
... CC cages are designed to facilitate an ... approach. These are interbody cages allowing radicular ... interve rtebral space and of the foramina, ... are particularly indicated for major lumbar instabilities.,CC ...
... SHELLGEL is a sterile nonpyrogenic, transparent ... SHELLGEL contains 12 mg/mL of high molecular ... hyaluronate dissolved in physiological saline. In the ... is 105,000 cps (105 Pa s) at ...
Medicine Products: